Beck Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Beck Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.76M	Sell	23,789 -164	-0.7%	-$22.2K	0.69%	47
2026 Q1	$3.06M	Buy	23,953 +2,152	+10%	+$269K	0.7%	51
2025 Q4	$2.66M	Buy	+21,801	New	+$2.5M	0.63%	54
2022 Q4	–	Sell	-19,588	Closed	-$1.55M	–	150
2022 Q3	$1.55M	Buy	+19,588	New	+$1.65M	0.67%	67
2019 Q3	–	Sell	-43,461	Closed	-$3.81M	–	116
2019 Q2	$3.81M	Sell	43,461 -1,576	-3%	-$134K	2.01%	17
2019 Q1	$4.08M	Buy	+45,037	New	+$3.83M	1.95%	16
2018 Q4	–	Sell	-75,539	Closed	-$7.24M	–	107
2018 Q3	$7.24M	Sell	75,539 -139	-0.2%	-$13.5K	3.11%	5
2018 Q2	$7.2M	Sell	75,678 -2,189	-3%	-$201K	3.48%	5
2018 Q1	$6.83M	Buy	77,867 +11,723	+18%	+$1.07M	3.14%	8
2017 Q4	$5.61M	Buy	66,144 +2,245	+4%	+$188K	2.47%	8
2017 Q3	$5.53M	Buy	63,899 +44,866	+236%	+$3.6M	2.64%	9
2017 Q2	$1.52M	Buy	19,033 +14,103	+286%	+$1M	0.78%	39
2017 Q1	$352K	Buy	+4,930	New	+$331K	0.19%	80
2014 Q2	–	Sell	-20,505	Closed	-$994K	–	167
2014 Q1	$994K	Sell	20,505 -2,940	-13%	-$150K	0.76%	44
2013 Q4	$1.17M	Buy	+23,445	New	+$971K	0.94%	34

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Beck Capital Management's XBI Position: Q2 2026 in Review

Beck Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.68% in Q2 2026, selling an estimated $22.2K and leaving 23,789 shares worth $3.76M. The position accounts for 0.69% of the portfolio, ranked #47.

Beck Capital Management first reported a position in XBI in Q4 2013 and has held it in 15 quarters since. The position peaked at $7.24M in Q3 2018. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Beck Capital Management held 23,789 shares of State Street SPDR S&P Biotech ETF worth $3.76M as of Q2 2026.
Beck Capital Management sold 164 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $22.2K.
State Street SPDR S&P Biotech ETF made up 0.69% of Beck Capital Management's portfolio in Q2 2026, its #47 holding.
Beck Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2013 and has held it in 15 quarters since.
Beck Capital Management's State Street SPDR S&P Biotech ETF position peaked at $7.24M in Q3 2018.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Beck Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.